secwatch.observer — SEC 8-K summary
======================================

Issuer:     Abpro Holdings, Inc. (ABPO)
CIK:        0001893219
Form:       8-K
Filed at:   2025-04-28T23:59:59+00:00
Accession:  0001213900-25-035735
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Abpro/Celltrion ABP-102/CT-P72 preclinical data at AACR 2025 shows potential best-in-class HER2 x CD3 T-cell engager
--------------------------------------------------------------------------------

- ABP-102/CT-P72 preclinical data presented orally at AACR 2025; co-developed with Celltrion via strategic partnership.
- Up to 2-fold increase in tumor suppression vs. runimotamab biosimilar in HER2-overexpressing cancer models.
- Reduced cytokine release and tolerated >180x the MTD of parental antibody in monkeys, suggesting wider therapeutic window.
- Phase 1 clinical trials planned to commence in first half of 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1893219/000121390025035735/0001213900-25-035735-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1893219/000121390025035735/ea0239349-8k_abprohold.htm
  HTML page:      https://secwatch.observer/filing/0001213900-25-035735

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer